The U.S. Food and Drug Administration has granted the designation for the company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA. In December 2022, Evaxion received FDA approval to proceed

AlzeCure Pharma has chosen a candidate drug (CD) and started the preclinical development phase with the company’s preventive and disease-modifying candidate drug Alzstatin ACD680. ACD680 is being developed within AlzeCure’s

Karolinska University Hospital’s cancer department has signed an agreement with Bristol Myers Squibb to start an oncology and hematology research collaboration focusing on advancing research and generating data with an

IRLAB Therapeutics has announced that a drug candidate has been nominated from the P003 research project. The drug candidate, IRL1117, will be developed as a once-daily oral treatment for the

BioArctic’s partner Eisai has announced that under the Accelerated Approval pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.: LEQEMBI) for the treatment

Alligator Bioscience has announced an expansion to its research collaboration and license agreement with Orion Corporation, to discover and develop together new bispecific antibody cancer therapeutics. The collaboration has been

Swedish Anocca has secured Venture Debt financing from the European Investment Bank (EIB). This significant investment recognizes the strength and high potential of Anocca and its transformational approach to developing

SynAct Pharma has entered into a conditional agreement on acquisition of TXP Pharma, a Swiss-incorporated biotech company researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases.

Oncopeptides has announced that the US Food and Drug Administration, FDA, has requested a withdrawal of the US marketing authorization for Pepaxto. The request is based on the outcome of

Nordic Nanovector and all shareholders of APIM Therapeutics have entered into a definitive merger agreement to combine the companies in an all-stock transaction. Subject to completion of the agreement, Nordic

Salipro Biotech has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target. The collaboration brings together Salipro Biotech’s

The company has opened an office in Boston to support its increasing US clinical development, partnering and fund-raising activities. The new office is at the CIC in Boston, Massachusetts which

Shanghai Henlius Biotech has received IND approval from China’s National Medical Products Administration for a Phase 2 clinical trial of AC101 in combination with anti-PD-1 monoclonal antibody HANSIZHUANG, HANQUYOU and

The company has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the company’s iTANK platform in arming CAR T-cells for

Mendus has announced an agreement to enable the technology transfer for manufacturing of the company’s lead development program DCP-001 with Minaris Regenerative Medicine. DCP-001 is currently being evaluated in the